Barclays’s Aerie Pharmaceuticals AERI Stock Holding History

Barclays’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-18,100	Closed	-$206K	–	4905
2021 Q3	$206K	Buy	+18,100	New	+$265K	﹤0.01%	3609
2019 Q2	–	Sell	-200	Closed	-$10K	–	7425
2019 Q1	$10K	Sell	200 -600	-75%	-$26.4K	﹤0.01%	6566
2018 Q4	$29K	Buy	800 +300	+60%	+$14.1K	﹤0.01%	5746
2018 Q3	$31K	Buy	+500	New	+$32.1K	﹤0.01%	6304
2018 Q1	–	Sell	-184,300	Closed	-$11M	–	7444
2017 Q4	$11M	Buy	+184,300	New	+$11.2M	0.01%	1134
2016 Q4	–	Sell	-10,000	Closed	-$377K	–	6915
2016 Q3	$377K	Buy	+10,000	New	+$221K	﹤0.01%	3460

Barclays's AERI Position: Q4 2022 in Review

Barclays sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 30,316 shares — an estimated $459K sold.

Barclays first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $9.25M in Q3 2016. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Barclays reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Barclays sold 30,316 Aerie Pharmaceuticals shares in Q4 2022, an estimated $459K.
Barclays first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
Barclays's Aerie Pharmaceuticals position peaked at $9.25M in Q3 2016.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.